Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal...
Novartis struck a collaboration with macrocycle biotech Unnatural Products targeting cardiovascular therapies, potentially worth up to $1.7 billion in milestones.
Why it mattersNovartis' $1.7 billion macrocycle cardio deal should prompt investors to prioritize macrocycle platforms.